ARTICLE 1 DEFINITIONSCollaboration and Option Agreement • April 15th, 2005 • Mymetics Corp • Biological products, (no disgnostic substances)
EX-10.46 3 dex1046.htm COLLABORATION AND OPTION AGREEMENT Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisk denote omissions. COLLABORATION AND OPTION AGREEMENT by and between Infinity...Collaboration and Option Agreement • May 5th, 2020 • Delaware
This Agreement is made this 16th day of November, 2004 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc. (“Infinity”), a Delaware corporation with principal offices at 780 Memorial Drive, Cambridge, Massachusetts 02139, and Novartis International Pharmaceutical Ltd. (“Novartis”), a Bermuda corporation with principal offices at Hurst Holme, 12 Trott Road, Hamilton, HM LX, Bermuda. Infinity and Novartis are sometimes referred to herein individually as a “Party” and together as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Collaboration and Option Agreement Between MORPHIC...Collaboration and Option Agreement • June 24th, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • New York
This Collaboration and Option Agreement (this “Agreement”) is made and entered into as of October 16, 2018, 2018 (the “Execution Date”) by and between Morphic Therapeutic, Inc., a Delaware corporation (“Morphic”) and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”). Morphic and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCollaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
ContractCollaboration and Option Agreement • June 16th, 2014 • Globeimmune Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
EX-10.11 16 a2236234zex-10_11.htm EX-10.11 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting...Collaboration and Option Agreement • May 5th, 2020 • England and Wales
This COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is made effective as of the “Effective Date” by and between ARIDIS PHARMACEUTICALS LLC, a company organized and existing under the laws of California having its registered office at 5941 Optical Court, San Jose, CA, 95138 USA (“ARIDIS”), and GLAXOSMITHKLINE BIOLOGICALS S.A., a company organized and existing under the laws of Belgium under number RPM Nivelles — BE — 0440 872918 and having its registered office at rue de l’Institut 89, 1330 Rixensart, Belgium (“GSK”). ARIDIS and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations • California
THIS COLLABORATION AND OPTION AGREEMENT (“Agreement”) dated as of December 22, 2010 (“Effective Date”), is entered into between XENCOR, INC., a Delaware corporation having its principal place of business at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”) and AMGEN INC., a Delaware corporation, having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”). Amgen and Xencor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein shall have the definitions set forth in Article 1.
EX-10.2(B) 3 d344523dex102b.htm AMENDMENT 1 TO THE COLLABORATION AND OPTION AGREEMENT [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been...Collaboration and Option Agreement • May 5th, 2020
THIS AMENDMENT 1 TO THE COLLABORATION AND OPTION AGREEMENT (the “Amendment”) is made and entered into on August 1st, 2012 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AND OPTION AGREEMENT BY AND BETWEEN ONCOMED PHARMACEUTICALS, INC. AND BAYER SCHERING PHARMA AG DATED JUNE 15, 2010Collaboration and Option Agreement • July 5th, 2012 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is made and entered into as of June 15, 2010 (the “Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Schering Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment # 2 to the Collaboration and Option AgreementCollaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations
This is a Second Amendment (“Amendment #2”) to the Collaboration and Option Agreement dated May 14th 2009 (the “Agreement) by and between Celgene Corporation, a Delaware Corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“Celgene”), and GlobeImmune, Inc., a Delaware Corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (“GlobeImmune”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Collaboration and Option Agreement • June 4th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATION AND OPTION AGREEMENT is entered into and made effective as of the 10th day of April, 2018 (the “Effective Date”), by and among:
AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • August 16th, 2012 • Globeimmune Inc • Pharmaceutical preparations
THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment # 1 to the Collaboration and Option AgreementCollaboration and Option Agreement • March 17th, 2014 • Globeimmune Inc • Pharmaceutical preparations
This is an Amendment (“Amendment”) to the Collaboration and Option Agreement dated May 14th 2009 (the “Agreement) by and between Celgene Corporation, a Delaware corporation having a place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“Celgene”), and GlobeImmune, Inc., a Delaware corporation having a place of business at 1450 Infinite Drive, Louisville, Colorado 80027 (“GlobeImmune”).
COLLABORATION AND OPTION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND ABBVIE IRELAND UNLIMITED COMPANY February 21, 2019Collaboration and Option Agreement • February 26th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Each Regulatory Milestone Payment set forth in Section 10.2.2(a) is payable only once for each Licensed Compound (e.g., if a [**]). Only one Regulatory Milestone Payment is payable for each Milestone Event for a Licensed Compound, even if multiple Licensed Products that contain or are comprised of such Licensed Compound achieve such Milestone Event. Only one Milestone Payment is payable for each Milestone Event for a Licensed Product, irrespective of the number of Licensed Compounds contained by such Licensed Product. By way of example and not limitation, if a Licensed Product containing or comprised of Licensed Compound x achieves the Milestone Event in Section 10.2.2(a)(ii), then no additional Milestone Payment shall be due if a different Licensed Product containing or comprised of Licensed Compound x achieves such Milestone Event.
Collaboration and option agreement for STT-5058Collaboration and Option Agreement • July 8th, 2024
Under the collaboration agreement, Staten will continue to develop its lead asset STT-5058 targeting ApoC3 for the treatment of dyslipidaemia, with support and R&D funding from Novo Nordisk.
AMENDMENT NO. 5 TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 11th, 2011 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 5 to the Agreement (this “Amendment No. 5”) is entered into as of November 1, 2010 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • May 21st, 2014 • Globeimmune Inc • Pharmaceutical preparations
THIS AMENDMENT #3 TO THE COLLABORATION AND OPTION AGREEMENT (together with any appendices attached hereto, this “Amendment #3”) is made and entered into as of June 16, 2011 (the “Amendment #3 Effective Date”), by and between GlobeImmune, Inc., a Delaware corporation located at 1450 Infinite Drive, Louisville, Colorado 80027, United States of America (“GlobeImmune”), and Celgene Corporation, a Delaware corporation located at 86 Morris Avenue, Summit, New Jersey 07901, United States of America (“Celgene”). GlobeImmune and Celgene are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 7 TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • May 4th, 2015 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 7 to the Agreement (this “Amendment No. 7”) is entered into as of March 19, 2015 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics” or “CK”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
AMENDMENT 2 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • November 13th, 2013 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT 2 TO THE COLLABORATION AND OPTION AGREEMENT (the “Amendment”) is made and entered into on August 27, 2013 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc. a Delaware corporation located at 800 Chesapeake Drive. Redwood City, California 94063. United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Re: Collaboration and Option Agreement between Fate Therapeutics, Inc. (“Fate”) and Ono Pharmaceutical Co., Ltd. (“Ono”), dated September 14, 2018 (the “Agreement”)Collaboration and Option Agreement • February 24th, 2021 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
As you know, Fate and Ono are conducting a research collaboration under the Agreement, pursuant to which (i) Fate is conducting research on Collaboration Candidate 1; and (ii) Ono and Fate are conducting research to enable Ono to determine the Ono Antigen Binding Domain for Collaboration Candidate 2, upon which determination the Ono Antigen Binding Domain will be incorporated into Collaboration Candidate 2 for further research and development of Collaboration Candidate 2 under the Agreement. Ono has exclusive options under the Agreement to obtain exclusive licenses to Collaboration Candidate 1 and Collaboration Candidate 2. Capitalized terms used but not defined in this letter will have the meanings given in the Agreement.
AMENDMENT 6 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • August 2nd, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 6 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on June 13, 2018 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany (“Bayer”). OncoMed and Bayer are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT 4 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • November 1st, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 4 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION AND OPTION AGREEMENT BY AND BETWEEN FATE THERAPEUTICS, INC. AND JANSSEN BIOTECH, INC. DATED APRIL 2, 2020Collaboration and Option Agreement • August 5th, 2020 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and Option Agreement (the “Agreement”) is made and entered into as of April 2, 2020 (the “Effective Date”), by and between Fate Therapeutics, Inc., a Delaware corporation located at 3535 General Atomics Court, Suite 200, San Diego, California 92121, United States of America (“Fate”), and Janssen Biotech, Inc., a Pennsylvania corporation located at 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044, United States of America (“Janssen”). Fate and Janssen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION Amendment #1 to the Collaboration and Option Agreement dated May 17, 2010 By and between Fluidigm Corporation and Novartis Vaccines and Diagnostics, Inc.Collaboration and Option Agreement • April 4th, 2011 • Fluidigm Corp • Laboratory analytical instruments
Incorporating the terms and conditions of the Collaboration and Option Agreement made effective May 17, 2010 (hereinafter referred to as the “Agreement”), made by and between Novartis Vaccines and Diagnostics, Inc. (“Novartis”) and Fluidigm Corporation (“Fluidigm”), the Agreement is amended, effective as of March 15, 2011.
First amendment to collaboration and option agreement forCollaboration and Option Agreement • July 14th, 2024 • New York
Akcea Therapeutics and Ionis Pharmaceuticals announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD).
Annex 1: Heads of Terms Collaboration and Option AgreementCollaboration and Option Agreement • December 14th, 2023 • England
This proposed transaction is subject to (i) the acceptance by both Parties of the principal terms as finally negotiated, and (ii) the negotiation, execution and delivery of a definitive Agreement. This Term Sheet does not constitute a binding contract, and the Parties do not intend to be legally bound, unless and until a definitive Agreement has been executed by both Parties. Unless and until a definitive Agreement has been executed by both Parties, either Party is free to terminate further negotiations at any time, with or without cause.
Collaboration and option agreement for cell therapy for cardiovascular applicationCollaboration and Option Agreement • July 22nd, 2024
Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002.
AMENDMENT TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • May 26th, 2005 • Myogen Inc • Pharmaceutical preparations
This Amendment to Collaboration and Option Agreement (“Amendment”) is entered into as of May 23, 2005 (the “Amendment Date”) by and between Myogen, Inc. (“Myogen”), a Delaware corporation with principal offices at 7575 W. 103rd Avenue, Westminster, Colorado 80021, and Novartis Institutes for BioMedical Research, Inc. (“NIBRI”), a Delaware corporation with principal offices at 400 Technology Square, Cambridge, Massachusetts 02139.
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Collaboration and Option Agreement • March 22nd, 2023 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances)
This letter ("Side Letter") relates to agreements between Senti Biosciences, Inc. ("Senti") and BlueRock Therapeutics LP (“BlueRock”) with respect to the Collaboration and Option Agreement between Senti and BlueRock dated May 21, 2021 (the “Agreement”). Any capitalized terms used herein but not otherwise defined herein shall have the meaning set forth in the Agreement.
AMENDMENT NO. 6 TO COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • August 7th, 2013 • Cytokinetics Inc • Pharmaceutical preparations
This Amendment No. 6 to the Agreement (this “Amendment No. 6”) is entered into as of June 11, 2013 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”).
Annex 1: Heads of Terms Collaboration and Option AgreementCollaboration and Option Agreement • August 22nd, 2024 • England
This proposed transaction is subject to (i) the acceptance by both Parties of the principal terms as finally negotiated, and (ii) the negotiation, execution and delivery of a definitive Agreement. This Term Sheet does not constitute a binding contract, and the Parties do not intend to be legally bound, unless and until a definitive Agreement has been executed by both Parties. Unless and until a definitive Agreement has been executed by both Parties, either Party is free to terminate further negotiations at any time, with or without cause.
AMENDMENT 5 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 9th, 2017 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 5 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into as of December 15, 2016 (the “Amendment Effective Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Collaboration and Option Agreement • February 14th, 2022 • Dynamics Special Purpose Corp. • Blank checks • Massachusetts
This COLLABORATION AND OPTION AGREEMENT (the “Agreement”), effective as of May 21, 2021 (the “Effective Date”), is made by and between SENTI BIOSCIENCES, INC., a Delaware corporation with its principal place of business at 2 Corporate Drive, South San Francisco, CA 94080 (“Senti”), and the BLUEROCK THERAPEUTICS LP, a Delaware limited partnership with its principal place of business at One Broadway, Floor Fifteen, Cambridge, MA 02142 (“BlueRock”). Senti and BlueRock are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCollaboration and Option Agreement • May 2nd, 2011
If the agreement is terminated by us at our sole discretion or by DSP under circumstances described in clauses (ii)(a) and (iii) above, then we will transfer our rights to the compounds and products developed under the agreement to DSP and will also grant to DSP a non-exclusive, perpetual, royalty-free license to certain intellectual property controlled by us necessary to continue the development of such compounds and products. If the agreement is terminated by us for a material breach by DSP, then, among other things, DSP will grant to us an exclusive, perpetual, paid-up license to all of the intellectual property of DSP necessary to continue the development, marketing and selling of the compounds and products subject to the agreement.
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 21st, 2024 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances)
This Collaboration and Option Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of November 6, 2023 (the “Effective Date”), by and between Senti Biosciences, Inc., a Delaware corporation with its principal place of business at 2 Corporate Drive, South San Francisco, CA 94080 (“Senti”), and Celest Therapeutics (Shanghai) Co. Ltd, a limited company organized under the laws of the People’s Republic of China, with its principal place of business at 3rd Floor, Building No. 1, 795 Kangwei Rd, Pudong, Shanghai, China, 201315 and uniform social credit code of 91310115MA1K4QQK97 (“Celest”). Senti and Celest are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
